April 01, 2025

FDA Monthly Round-Up: Key March Updates

March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.

Conexiant

April 01, 2025

GEM Helps Put T2D in Remission

Researchers highlight evidence-based lifestyle and pharmacologic strategies, including glycemic excursion minimization and tirzepatide, for early glycemic control in adults with type 2 diabetes.

Conexiant

April 01, 2025

Medical Oddities: Shrinking Brains, Failing Hearts?

Brains shrink, bots soothe, tea disappoints, and love gets the hormonal spotlight it deserves this week.

Conexiant

March 31, 2025

Tariff Threat: Drugs Could Cost U.S. $750M More

New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.

Conexiant

March 31, 2025

Microplastics Linked to Cardiovascular Disease

Research reveals significant associations between environmental microplastic pollution and increased rates of hypertension, diabetes, and stroke across U.S. coastal communities, with pollution levels ranking among top predictors for chronic disease prevalence.

Conexiant

March 28, 2025

FDA Declines Cardamyst Approval Request

The FDA declined to approve Milestone’s etripamil nasal spray for PSVT, citing manufacturing issues and a need for more data on impurities, but raised no safety or efficacy concerns.

Reuters

March 28, 2025

T2D: Non-traditional CVD Risk Factors

Investigators identify and rank non-traditional risk factors for cardiovascular disease prediction.

Conexiant

March 28, 2025

Cancer–Heart Death Link Exposed

Colorectal cancer patients face up to 45% higher cardiovascular mortality risk within two years of diagnosis, with Black patients and those under 50 experiencing the greatest danger, according to research presented at ACC.25.

Conexiant

March 27, 2025

Trends in Spironolactone Prescribing Among Young Women

A cohort study of 38 million insured females aged 12 to 40 years found a marked increase in spironolactone prescriptions, most commonly for acne and other androgen-related conditions.

Conexiant